We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

60 hedge funds and large institutions have $15.3M invested in Seelos Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

319% more call options, than puts

Call options by funds: $381K | Put options by funds: $91K

2% less capital invested

Capital invested by funds: $15.6M → $15.3M (-$263K)

5% less funds holding

Funds holding: 63 → 60 (-3)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

38% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 13

Holders
60
Holders Change
-3
Holders Change %
-4.76%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
8
Reduced
13
Closed
11
Calls
$381K
Puts
$91K
Net Calls
+$290K
Net Calls Change
-$17K

Top Buyers

Rank Fund Capital Flow
1
WE
Wealth Effects
Massachusetts
+$729K
2
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
+$161K
3
GJL
Gendell Jeffrey L
+$123K
4
IAIM
International Assets Investment Management
Florida
+$52.7K
5
TCOT
Trust Company of Toledo
Ohio
+$41K

Top Sellers

Rank Fund Capital Flow
1
Group One Trading
Group One Trading
Illinois
-$735K
2
OMC
Oasis Management Company
Cayman Islands
-$577K
3
BlackRock
BlackRock
New York
-$93.7K
4
Millennium Management
Millennium Management
New York
-$93.7K
5
GCP
GSA Capital Partners
United Kingdom
-$71K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$36.5K – – –
BAM
27
Belpointe Asset Management
Nevada
$34.6K – – –
AMC
28
Asset Management Corp
Illinois
$28K +$32.2K +11 New
Charles Schwab
29
Charles Schwab
California
$27.1K – – –
SG Americas Securities
30
SG Americas Securities
New York
$26K -$5.86K -2 -17%
HSBC Holdings
31
HSBC Holdings
United Kingdom
$24.9K -$5.86K -2 -18%
Wells Fargo
32
Wells Fargo
California
$21.2K – – –
Deutsche Bank
33
Deutsche Bank
Germany
$21.1K -$23.4K -8 -50%
FHC
34
First Heartland Consultants
Missouri
$20.2K – – –
CA
35
Crewe Advisors
Utah
$19.2K – – –
UBV
36
United Bank (Virginia)
Virginia
$18.1K – – –
CHA
37
Carmichael Hill & Associates
Maryland
$14.5K +$5.86K +2 +67%
Stifel Financial
38
Stifel Financial
Missouri
$14.3K – – –
Goldman Sachs
39
Goldman Sachs
New York
$14.1K – – –
DFG
40
Delta Financial Group
New Jersey
$14K – – –
JP Morgan Chase
41
JP Morgan Chase
New York
$14K +$14.6K +5 New
Jane Street
42
Jane Street
New York
$12.6K +$14.6K +5 New
VFA
43
Valeo Financial Advisors
Indiana
$10.5K – – –
RVPG
44
Relative Value Partners Group
$10.4K – – –
IWC
45
Integrated Wealth Concepts
Massachusetts
$10K +$11.7K +4 New
Victory Capital Management
46
Victory Capital Management
Texas
$8.05K – – –
First Manhattan
47
First Manhattan
New York
$7.72K -$2.93K -1 -25%
ACI
48
Alpha Cubed Investments
California
$7.6K – – –
ACA
49
Aptus Capital Advisors
Alabama
$7.24K – – –
GWANC
50
Guardian Wealth Advisors (North Carolina)
North Carolina
$7.23K – – –
1
2
3 4

SEEL Hedge Fund Activity: Q1 2023 in Review

60 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q1 2023, worth a combined $15.3M — down 1.7% from $15.6M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of SEEL and 8 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 8 added.

The largest buyer was Wealth Effects, opening a new position worth an estimated $729K. The largest seller was Group One Trading, cutting an estimated $735K.

  • 60 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q1 2023, down from 63 in Q4 2022.
  • Funds reported $15.3M of Seelos Therapeutics, Inc. Common Stock stock for Q1 2023, down 1.7% quarter-over-quarter.
  • 8 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q1 2023 and 11 closed out, a net change of -3 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q1 2023 was Wealth Effects, an estimated $729K added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q1 2023 was Group One Trading, an estimated $735K sold.

Based on aggregated 13F filings for Q1 2023.